Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Research & Development (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Research & Development for 3 consecutive years, with $25.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 24.03% to $25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $113.0 million through Dec 2025, down 44.52% year-over-year, with the annual reading at $113.0 million for FY2025, 44.52% down from the prior year.
  • Research & Development for Q4 2025 was $25.3 million at Inhibrx Biosciences, down from $28.5 million in the prior quarter.
  • The five-year high for Research & Development was $82.1 million in Q4 2023, with the low at $22.3 million in Q2 2025.
  • Average Research & Development over 3 years is $42.8 million, with a median of $36.9 million recorded in 2025.
  • The sharpest move saw Research & Development soared 98.3% in 2024, then crashed 67.08% in 2025.
  • Over 3 years, Research & Development stood at $82.1 million in 2023, then plummeted by 59.35% to $33.4 million in 2024, then fell by 24.03% to $25.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $25.3 million, $28.5 million, and $22.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.